Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2017

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms DuoSleep
  • Sponsors Novartis
  • Most Recent Events

    • 05 May 2017 Status changed from recruiting to completed.
    • 13 Sep 2016 This trial has been completed in Sweden (end date: 22 Jun 2016), according to the European Clinical Trials Database.
    • 03 Aug 2016 This trial has been completed in Denmark (end date: 22 Jun 2016), according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top